CJC-1295

CJC-1295 is arguably the most popular growth hormone-releasing hormone (GHRH) analog in the anti-aging and peptide therapy landscape, and also one of the most confusing. The confusion stems from a simple problem: "CJC-1295" refers to two fundamentally different molecules with different pharmacokinetics, different dosing protocols, and different safety profiles. One has a Drug Affinity Complex (DAC) that extends its half-life to nearly a week. The other — sometimes called CJC-1295 no-DAC or Mod GRF 1-29 — has a half-life measured in minutes. They are not interchangeable, and conflating them leads to bad dosing decisions, unexpected side effects, and clinical outcomes that don't match expectations.

This guide untangles the CJC-1295 confusion, covers the actual human trial data for both variants, explains the critical pharmacokinetic differences, reviews vendor testing data from 47 vendors across 245 tested samples, and provides evidence-based context for the most common clinical applications. If you've been prescribed CJC-1295 or are considering it, the first thing you need to know is which CJC-1295 we're talking about.

What Is CJC-1295?

CJC-1295 was originally developed by ConjuChem Biotechnologies (now Encycle Therapeutics) as a long-acting GHRH analog designed to provide sustained growth hormone release with less frequent dosing than natural GHRH or shorter-acting analogs like sermorelin.

The Original: CJC-1295 with DAC

The original CJC-1295 is a 30-amino-acid peptide based on a modified GHRH(1-29) sequence with four amino acid substitutions (at positions 2, 8, 15, and 27) that protect it from enzymatic degradation by DPP-IV. Critically, it also includes a Drug Affinity Complex — a maleimidopropionic acid linker that allows the peptide to covalently bind to serum albumin after injection.

[CITATION: PubMed study needed on CJC-1295 DAC structure and albumin binding mechanism]

This albumin binding is what gives CJC-1295 DAC its defining characteristic: a plasma half-life of approximately 6-8 days. For comparison, natural GHRH has a half-life of roughly 7-10 minutes, sermorelin approximately 10-20 minutes, and even tesamorelin has a half-life measured in hours. CJC-1295 DAC's week-long half-life means a single injection produces sustained GHRH receptor stimulation for days.

The Derivative: CJC-1295 Without DAC (Mod GRF 1-29)

CJC-1295 without DAC — more accurately called Modified GRF(1-29) or tetrasubstituted GRF(1-29) — contains the same four amino acid substitutions as the DAC version but lacks the albumin-binding linker. Without the DAC, the peptide has a half-life of approximately 30 minutes — far longer than natural GHRH but dramatically shorter than the DAC version.

The distinction is not trivial. CJC-1295 DAC produces sustained, relatively flat GH elevation over days. Mod GRF 1-29 produces an acute GH pulse that peaks within 30-60 minutes and dissipates within a few hours. These are fundamentally different pharmacokinetic profiles that produce different physiological effects.

Why the Confusion Exists

The peptide vendor market routinely sells Mod GRF 1-29 labeled simply as "CJC-1295" — sometimes without clarifying whether it's the DAC or no-DAC version. This creates real clinical problems because:

• Dosing protocols for DAC and no-DAC versions are completely different (weekly vs. multiple times daily)
• The DAC version produces non-physiological sustained GH elevation; the no-DAC version produces more pulsatile release
• Side effect profiles differ in important ways
• Combining them with other secretagogues requires different approaches

When evaluating any CJC-1295 protocol, the first question should always be: DAC or no DAC?

How CJC-1295 Works

GHRH Receptor Mechanism

Both CJC-1295 variants bind to the GHRH receptor on anterior pituitary somatotroph cells, triggering the same Gs/cAMP/PKA signaling cascade as endogenous GHRH. The four amino acid substitutions don't alter receptor binding affinity meaningfully — they primarily improve metabolic stability by protecting against DPP-IV cleavage at position 2 and other enzymatic degradation sites.

[CITATION: PubMed study needed on modified GRF analogs and DPP-IV resistance]

GH Amplification vs. GH Initiation

An important mechanistic nuance: GHRH analogs like CJC-1295 primarily amplify GH release rather than initiate it entirely de novo. The pituitary somatotroph cells have intrinsic pulsatile GH secretion patterns regulated by the interplay of hypothalamic GHRH and somatostatin. CJC-1295 amplifies the GH pulses by increasing the amount of GH released per pulse. This is why CJC-1295 (particularly the no-DAC version) is most effective when administered during natural GH pulse windows — typically before sleep or in the fasting state.

The DAC Difference in Mechanism

CJC-1295 DAC's continuous albumin-bound circulation means it provides persistent GHRH receptor stimulation regardless of natural pulsatility. This raises a legitimate mechanistic concern: sustained (non-pulsatile) GHRH receptor activation could theoretically lead to receptor desensitization over time, potentially blunting the GH response. Some clinical data supports this concern — the GH response to CJC-1295 DAC appears to diminish somewhat with repeated dosing, though IGF-1 levels remain elevated.

[CITATION: PubMed study needed on CJC-1295 DAC tachyphylaxis and sustained GHRH receptor stimulation]

Mod GRF 1-29, with its short half-life, produces discrete pulses more similar to natural GHRH patterns. This pulsatile stimulation is less likely to cause receptor desensitization and may better preserve the physiological GH pulse architecture. This is the primary theoretical argument for preferring the no-DAC version, despite the convenience advantage of the DAC version.

Human Trial Data

CJC-1295 has limited but meaningful human data — more than many research peptides but far less than FDA-approved compounds like tesamorelin.

Phase I/II Trials (DAC Version)

The original ConjuChem clinical trials evaluated CJC-1295 DAC in healthy subjects and demonstrated:

GH elevation: Single doses of CJC-1295 DAC (30-60 mcg/kg) produced sustained GH elevation for 6+ days, with mean GH levels 2-10 fold above baseline depending on the dose. The GH elevation was not constant — it showed pulsatile peaks superimposed on an elevated baseline, suggesting that endogenous pulsatility was amplified rather than replaced.

[CITATION: PubMed study needed on CJC-1295 DAC Phase I GH response data]

IGF-1 increase: IGF-1 levels increased by 46-84% from baseline, with peak effects occurring 8-11 days after injection and sustained elevation for up to 28 days. This prolonged IGF-1 elevation reflects both the direct GH effects and the slow pharmacokinetic clearance of the albumin-bound peptide.

[CITATION: PubMed study needed on CJC-1295 DAC IGF-1 elevation in human subjects]

Dose-response: Clear dose-dependent responses were observed, with higher doses producing greater and more sustained GH and IGF-1 elevation. However, the dose-response curve showed diminishing returns at higher doses, suggesting receptor saturation or feedback-mediated attenuation.

Safety Signal: The Death That Changed Everything

The CJC-1295 DAC clinical development program was halted after a participant death during Phase II trials. The participant died of a myocardial infarction (heart attack), and while a direct causal link to CJC-1295 DAC was never definitively established, the event was sufficient to terminate the clinical program.

[CITATION: PubMed study needed on CJC-1295 DAC clinical trial termination]

This safety signal is important context for anyone considering CJC-1295 DAC. The death may have been unrelated to the drug — myocardial infarctions occur in study populations regardless of treatment — but the absence of completed Phase III safety data means we don't have the statistical power to fully characterize cardiovascular risk. This uncertainty is qualitatively different from the uncertainty around peptides that simply haven't been tested; CJC-1295 DAC's program was specifically terminated due to a safety concern.

Mod GRF 1-29 Human Data

Direct human trial data specifically on Mod GRF 1-29 as a standalone compound is more limited. Most human data on modified GRF(1-29) analogs comes from broader GHRH analog research and from studies that used similar tetrasubstituted GRF sequences as pharmacological tools rather than therapeutic candidates.

The human data that does exist confirms that Mod GRF 1-29 produces acute GH pulses peaking 15-30 minutes after subcutaneous injection, with GH levels returning to baseline within 2-3 hours. The magnitude of GH release is enhanced when combined with ghrelin-mimetic secretagogues like ipamorelin — which is why the "CJC-1295/ipamorelin" combination has become the most widely prescribed secretagogue protocol.

The CJC-1295/Ipamorelin Combination

This combination deserves its own section because it has become the de facto standard protocol in peptide therapy clinics. The rationale is synergistic GH release through complementary receptor activation:

• CJC-1295 (Mod GRF 1-29) stimulates the GHRH receptor, "priming" somatotroph cells for GH release
• Ipamorelin stimulates the GHS receptor (ghrelin receptor), amplifying the magnitude of the GH pulse

[CITATION: PubMed study needed on synergistic GH release from combined GHRH and ghrelin-mimetic administration]

The combined GH response is typically 2-3x greater than either peptide alone. The clinical protocol usually involves:

• Mod GRF 1-29: 100-300 mcg
• Ipamorelin: 100-300 mcg
• Administered together subcutaneously, typically at bedtime on an empty stomach
• Often prescribed 5-7 nights per week

This combination is theoretically elegant — two different receptor pathways converging on maximized GH pulse amplitude while preserving pulsatile release patterns. The practical question is whether the magnitude of GH increase translates to clinically meaningful outcomes in body composition, recovery, sleep, and aging. Controlled clinical trial data specifically on this combination for anti-aging endpoints is largely absent, with most evidence being clinical experience and patient-reported outcomes.

Vendor Testing Data: 47 Vendors, 245 Samples

Our testing database for CJC-1295 (both DAC and no-DAC variants combined) represents one of the largest peptide testing datasets in our system: 47 vendors across 245 samples.

Purity Results

• Mean purity: 92.8%
• Median purity: 94.1%
• Samples exceeding 95% purity: 55%
• Samples below 90% purity: 22%
• Samples below 85% purity: 9%

The 22% of samples falling below 90% purity is concerning. Common impurities include oxidized methionine variants, deamidated forms, and truncated sequences. The no-DAC variant (Mod GRF 1-29) tended to have slightly higher purity than the DAC version across vendors, likely because the DAC conjugation adds a complex synthesis step that can introduce additional impurities.

Quantity Accuracy

• Within 10% of labeled quantity: 68%
• Overcount (more than labeled): 11%
• Undercount (less than labeled): 32%

The 32% undercount rate means nearly one-third of samples contained less CJC-1295 than labeled — patients using these products would receive a lower effective dose than intended.

DAC vs. No-DAC Labeling

A particularly concerning finding: 8% of samples labeled as "CJC-1295 with DAC" showed no evidence of DAC conjugation on analysis, suggesting they were actually the no-DAC variant mislabeled as the DAC version. Given the dramatically different pharmacokinetics and dosing protocols, this mislabeling is clinically hazardous.

For vendor-specific data, see our peptide vendor testing database and peptide purity guide.

Dosing Protocols

CJC-1295 with DAC

• Standard dose: 1-2 mg subcutaneously once or twice weekly
• Timing: Can be administered at any time (sustained release makes timing less critical)
• Duration: Typically prescribed in 3-6 month cycles with monitoring

CJC-1295 Without DAC (Mod GRF 1-29)

• Standard dose: 100-300 mcg subcutaneously
• Frequency: 1-3 times daily, most commonly at bedtime
• Timing: On an empty stomach, typically 90+ minutes after last food intake
• Common combination: Combined with ipamorelin 100-300 mcg at the same injection

Food and Timing Considerations

Both variants work better in a fasted state. Blood glucose, free fatty acids, and insulin all suppress GH release through direct pituitary effects and enhanced somatostatin tone. Carbohydrate-rich meals are particularly suppressive. Most protocols recommend no food for at least 90 minutes before and 30-60 minutes after injection.

Side Effects

Common Effects (Both Variants)

• Injection site reactions: redness, swelling, pain (10-20%)
• Facial flushing: transient warmth after injection (15-25%)
• Headache: typically mild, more common in the first week (5-10%)
• Water retention: mild peripheral edema (5-8%)

DAC-Specific Concerns

• Sustained GH elevation may cause more persistent side effects compared to the acute, transient effects of the no-DAC version
• Greater theoretical risk of GH-mediated insulin resistance due to continuous (non-pulsatile) GH stimulation
• Potential for cumulative effects with weekly dosing if clearance is slower than expected

Serious Considerations

• The terminated Phase II trial and participant death remain an unresolved safety signal for the DAC version
• IGF-1 elevation carries theoretical cancer promotion risk
• Glucose metabolism should be monitored, particularly in patients with pre-existing insulin resistance
• Joint pain and carpal tunnel syndrome can occur with excessive GH/IGF-1 elevation

CJC-1295 vs. Other Secretagogues

vs. Sermorelin

Sermorelin is a simpler GHRH fragment (1-29 without amino acid substitutions). CJC-1295 no-DAC (Mod GRF 1-29) has better metabolic stability due to its four amino acid substitutions. In practice, Mod GRF 1-29 has largely replaced sermorelin in clinical protocols because it produces more consistent GH stimulation per injection.

vs. Tesamorelin

Tesamorelin has FDA approval and Phase III data, which CJC-1295 lacks. However, CJC-1295 (particularly the no-DAC version combined with ipamorelin) is more widely available through compounding pharmacies and is typically less expensive. The evidence-quality trade-off favors tesamorelin; the accessibility and cost trade-off favors CJC-1295.

vs. MK-677

MK-677 is oral and works through the ghrelin receptor, while CJC-1295 works through the GHRH receptor. They can theoretically be combined, though the sustained GH elevation from MK-677 plus the sustained elevation from CJC-1295 DAC could produce excessive and non-physiological GH levels. CJC-1295 no-DAC is more commonly combined with ipamorelin (a cleaner ghrelin-mimetic than MK-677) rather than MK-677.

The Bottom Line

CJC-1295 is a peptide where the details matter enormously. The DAC and no-DAC versions are fundamentally different molecules with different risk profiles, dosing requirements, and clinical applications. The no-DAC version (Mod GRF 1-29), particularly when combined with ipamorelin, has become the most popular secretagogue protocol in anti-aging medicine — but this popularity is driven more by clinical experience than by controlled trial data.

The DAC version carries the unresolved safety signal from the terminated clinical program. The no-DAC version has a more favorable theoretical safety profile due to its pulsatile GH stimulation pattern but less human data to confirm this advantage.

For anyone considering CJC-1295, the essential steps are: confirm which variant you're being prescribed, verify vendor quality through third-party testing, ensure proper baseline and monitoring labs (IGF-1, fasting glucose, HbA1c), and work with a clinician who understands the distinction between DAC and no-DAC pharmacokinetics.

For broader context, see our profiles on ipamorelin, sermorelin, tesamorelin, GHRP-2, and hexarelin.